Peptides for Recovery
Reviewed by Marcus Hopkin, PhD
Director of Research and Development, Volta Peptides
Written by Volta Peptides Editorial Team · Reviewed September 15, 2026
This guide provides an in-depth examination of two peptides that have been the focus of research related to recovery. The compounds are ranked based on the strength of available evidence, from those with FDA approval to those still in early preclinical stages. Each peptide is analyzed for its mechanisms of action, clinical status, and safety profiles, offering a comprehensive understanding of their potential roles in recovery applications.
Overview
Research into peptides for recovery has gained traction as scientists explore their potential to enhance healing and physiological restoration. This guide highlights two prominent peptides: Somatropin, which has garnered FDA approval, and CJC-1295 with DAC, currently in early-phase clinical trials. The evidence supporting these compounds varies significantly, with Somatropin demonstrating established efficacy in treating growth hormone deficiencies, while CJC-1295 with DAC presents a novel approach to sustained growth hormone elevation. Understanding the mechanisms, clinical contexts, and safety profiles of these peptides is crucial for researchers aiming to leverage their properties in recovery-focused studies.
Somatropin (rHGH) — FDA-Approved
Evidence Rating: A
Category: Growth Hormone
Somatropin, a recombinant form of human growth hormone (rHGH), consists of 191 amino acids and is structurally identical to the endogenous hormone produced by the pituitary gland. Unlike growth hormone secretagogues that stimulate endogenous release, somatropin acts as a direct replacement therapy. Clinical studies have robustly established its efficacy in treating growth hormone deficiency in both children and adults. For instance, studies indicate that somatropin effectively promotes linear growth in children with GH deficiencies, leading to significant improvements in height and overall growth metrics. Additionally, it has been shown to enhance muscle mass and reduce fat mass in adults, contributing to improved body composition. Its safety profile is well-documented, with common side effects being mild and manageable, reinforcing its status as a reliable therapeutic option.
CJC-1295 with DAC — Phase I-II data; research compound
Evidence Rating: C
Category: Growth Hormone
CJC-1295 with DAC (Drug Affinity Complex) represents a modified analog of growth hormone-releasing hormone (GHRH). This peptide features a unique lysine-linked maleimidopropionic acid moiety that allows it to covalently bind to circulating albumin in vivo, significantly extending its half-life from mere minutes (as seen with native GHRH) to approximately 8 days. This extended duration facilitates less frequent dosing, typically once or twice a week, while maintaining elevated levels of growth hormone. Research suggests that this continuous elevation can be advantageous for certain therapeutic strategies; however, it also leads to a non-physiological release pattern, which may limit its applicability in contexts where natural pulsatile release is preferred. Early-phase clinical studies have indicated promising results, yet the evidence remains limited, necessitating further investigation to fully elucidate its efficacy and safety in recovery applications.
Shop Research Peptides
CJC-1295 DAC 5mg
Cagrilintide 5mg
DSIP 10mg
Epithalon 10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Peptide Tools
Key research references
- Best Peptides for Anti-Aging | Research Guide
- Best Peptides for Metabolic Health | Research Guide
- Best Peptides for Weight Management | Research Guide
- Best Peptides for Body Composition | Research Guide
- Best Peptides for Reproductive Health | Research Guide
- Best Peptides for Anti-Aging & Longevity | Research Guide
- Best Peptides for Weight Loss | Research Guide
- Best Peptides for Cognitive Enhancement | Research Guide
- Retatrutide Dosing Guide | Protocols & Reconstitution
- Wound Healing Peptides | Research Compounds
- Muscle Growth Peptides | Research Compounds
- Immune Modulation Peptides | Research Compounds
Browse the research catalogue
Buying and verification
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
SubscribeFrequently Asked Questions
Related Resources
Related Research
About the reviewer
Director of Research and Development, Volta Peptides
Marcus Hopkin, PhD, is Director of Research and Development at Volta Peptides. He has more than 12 years of analytical chemistry experience, including direct laboratory work in peptide synthesis, characterization, purity testing and stability assessment. His doctoral research at the University of Michigan examined novel peptide structures in the human proteome and their potential significance for therapeutic-peptide research. Before joining Volta Peptides he held research and development roles at Amgen and Eli Lilly and Company, and served as a lecturer at the University of Michigan.
Marcus reviewed this article for scientific and analytical accuracy on September 15, 2026. He did not write it. Technical review is internal review and is not peer review, independent third-party review or medical review.
Disclosure. Marcus Hopkin is an employee of Volta Peptides and serves as its Director of Research and Development. Volta Peptides sells research compounds related to subjects discussed in the content he writes and reviews. His reviews are internal scientific and technical review and must not be described as independent third-party review, peer review or medical review.